Pharmaceutical

Sanofi signs agreement to acquire Inhibrx for $1.7bn

Sanofi has signed a definitive agreement for the acquisition of all outstanding shares of Inhibrx for an equity value of $1.7bn.

Jan 23, 2024 - 18:00
Sanofi signs agreement to acquire Inhibrx for $1.7bn
Sanofi has signed a definitive agreement for the acquisition of all outstanding shares of Inhibrx for an equity value of $1.7bn.
Read the original article

Tags:

Previous Article

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Next Article

Inhalation Sciences and Actarmo enter respiratory drugs collaboration

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT unveils a new look, and color. Our executive editor explains why

STAT unveils a new look, and color. Our executive edito...

Jun 28, 2023

STAT+: As demand for Covid shots wanes, Moderna seeks its next success

STAT+: As demand for Covid shots wanes, Moderna seeks i...

Jun 26, 2023

STAT+: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments

STAT+: U.K. unveils $800 million package to bolster lif...

May 25, 2023